Advertisement
Biological Psychiatry
Advanced SearchSave search
Correspondence| Volume 77, ISSUE 3, e19-e20, February 01, 2015

Serum Interleukin-6 Is a Predictive Biomarker for Ketamine’s Antidepressant Effect in Treatment-Resistant Patients With Major Depression

Published:July 08, 2014DOI:https://doi.org/10.1016/j.biopsych.2014.06.021
Serum Interleukin-6 Is a Predictive Biomarker for Ketamine’s Antidepressant Effect in Treatment-Resistant Patients With Major Depression
Previous ArticleLooking Beyond the Role of Glycogen Synthase Kinase-3 Genetic Expression on Electroretinogram Response: What About Lithium?
Next ArticleEditorial Board Page
      The N-methyl-D-aspartate receptor antagonist ketamine is the most attractive antidepressant therapy for treatment-resistant patients with major depressive disorder (MDD) and bipolar disorder (
      • Aan Het Rot M.
      • Zarate Jr, C.A.
      • Charney D.S.
      • Mathew S.J.
      Ketamine for depression: Where do we go from here?.
      Biol Psychiatry. 2012; 72: 537-547
      ,
      • Krystal J.H.
      • Sanacora G.
      • Duman R.S.
      Rapid-acting glutamatergic antidepressants: The path to ketamine and beyond.
      Biol Psychiatry. 2013; 73: 1133-1141
      ). A single subanesthetic dose (.5 mg/kg) of ketamine produces a rapid antidepressant effect in two thirds of these patients, which can last for over a week (
      • Zarate Jr, C.A.
      • Brutsche N.E.
      • Laje G.
      • Luckenbaugh D.A.
      • Venkata S.L.V.
      • Ramamoorthy A.
      • et al.
      Relationship of ketamine’s plasma metabolites with response, diagnosis, and side effects in major depression.
      Biol Psychiatry. 2012; 72: 331-338
      ,
      • Murrough J.W.
      • Iosifescu D.V.
      • Chang L.C.
      • Al Jurdi R.K.
      • Green C.E.
      • Perez A.M.
      • et al.
      Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial.
      Am J Psychiatry. 2013; 170: 1134-1142
      ). However, biomarkers able to differentiate between responding and nonresponding patients have yet to be identified (
      • Zarate Jr, C.A.
      • Brutsche N.E.
      • Laje G.
      • Luckenbaugh D.A.
      • Venkata S.L.V.
      • Ramamoorthy A.
      • et al.
      Relationship of ketamine’s plasma metabolites with response, diagnosis, and side effects in major depression.
      Biol Psychiatry. 2012; 72: 331-338
      ,
      • Zarate Jr, C.A.
      • Mathews D.C.
      • Furey M.L.
      Human biomarkers of rapid antidepressant effects.
      Biol Psychiatry. 2013; 73: 1142-1155
      ).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Aan Het Rot M.
        • Zarate Jr, C.A.
        • Charney D.S.
        • Mathew S.J.
        Ketamine for depression: Where do we go from here?.
        Biol Psychiatry. 2012; 72: 537-547
        View in Article
        • Krystal J.H.
        • Sanacora G.
        • Duman R.S.
        Rapid-acting glutamatergic antidepressants: The path to ketamine and beyond.
        Biol Psychiatry. 2013; 73: 1133-1141
        View in Article
        • Zarate Jr, C.A.
        • Brutsche N.E.
        • Laje G.
        • Luckenbaugh D.A.
        • Venkata S.L.V.
        • Ramamoorthy A.
        • et al.
        Relationship of ketamine’s plasma metabolites with response, diagnosis, and side effects in major depression.
        Biol Psychiatry. 2012; 72: 331-338
        View in Article
        • Murrough J.W.
        • Iosifescu D.V.
        • Chang L.C.
        • Al Jurdi R.K.
        • Green C.E.
        • Perez A.M.
        • et al.
        Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial.
        Am J Psychiatry. 2013; 170: 1134-1142
        View in Article
        • Zarate Jr, C.A.
        • Mathews D.C.
        • Furey M.L.
        Human biomarkers of rapid antidepressant effects.
        Biol Psychiatry. 2013; 73: 1142-1155
        View in Article
        • Erhardt S.
        • Lim C.K.
        • Linderholm K.R.
        • Janelidze S.
        • Lindqvist D.
        • Samuelsson M.
        • et al.
        Connecting inflammation with glutamate agonism in suicidality.
        Neuropsychopharmacology. 2013; 38: 743-752
        View in Article
        • Miller A.H.
        • Maletic V.
        • Raison C.L.
        Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression.
        Biol Psychiatry. 2009; 65: 732-741
        View in Article
        • Serafini G.
        • Pompili M.
        • Elena Seretti M.
        • Stefani H.
        • Palermo M.
        • Coryell W.
        • Girardi P.
        The role of inflammatory cytokines in suicidal behavior: A systematic review.
        Eur Neuropsychopharmacol. 2013; 23: 1672-1686
        View in Article
        • Maes M.
        • Anderson G.
        • Kubera M.
        • Berk M.
        Targeting classical IL-6 signalling or IL-6 trans-signalling in depression?.
        Expert Opin Ther Targets. 2014; 18: 495-512
        View in Article
        • Zunszain P.A.
        • Horowitz M.A.
        • Cattaneo A.
        • Lupi M.M.
        • Pariante C.M.
        Ketamine: Synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties.
        Mol Psychiatry. 2013; 18: 1236-1241
        View in Article

      Article Info

      Publication History

      Published online: July 08, 2014

      Identification

      DOI: https://doi.org/10.1016/j.biopsych.2014.06.021

      Copyright

      © 2015 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2022 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX